Can promising cancer vaccine results trigger a massive rally in a drugmaker’s stock? Shares of Sellas Life Sciences Group Inc. surged 156% on November 17, 2026, after the company reported positive late-stage clinical trial results for its experimental cancer vaccine, galinpepimut-S (GPS), targeting acute myeloid leukaemia (AML), an aggressive form of blood cancer.
The stock recorded its biggest single-day gain since 2020 and climbed as much as 233% during Tuesday’s trading session.
Cancer Vaccine Shows Promising Survival Results
According to the company, the experimental vaccine reduced the risk of death by 41% compared with the best available treatment for patients with AML.
Patients receiving galinpepimut-S achieved a median overall survival of 24 months, compared with less than 15 months among those receiving other treatments. These findings have raised expectations about the vaccine’s potential as a new treatment option for this aggressive blood cancer.
$150 Million Share Sale Follows Stock Rally
Following the sharp rise in its share price, Sellas announced a $150 million share sale through JPMorgan and TD Cowen. However, the announcement triggered a decline of around 12% in the stock during extended trading.
Meanwhile, analysts viewed the clinical trial results as a significant development for cancer vaccine research. Alliance Global Partners analyst James Molloy described the findings as potentially significant for AML treatment and said the vaccine could become a standard treatment option if approved.
How Does the Experimental Cancer Vaccine Work?
Galinpepimut-S is an off-the-shelf experimental vaccine made from synthetic peptides designed to stimulate the immune system against WT1, a protein found in most cases of acute myeloid leukaemia.
Researchers at Memorial Sloan Kettering Cancer Centre developed the vaccine, which the institution licensed to Sellas in 2014.
The development adds to growing interest in cancer vaccines, particularly following research into personalised cancer vaccines targeting melanoma by Moderna and Merck.
However, the stock rally also attracted attention from short sellers. According to S3 Partners data, short interest in Sellas increased to 29% of its free float following Tuesday’s surge.
The trial findings have generated optimism about the potential role of cancer vaccines in treating aggressive blood cancers, although further regulatory evaluation will determine whether galinpepimut-S can become an approved treatment option. As reported by cnbctv18.com, Sellas Life Sciences witnessed a sharp rise in its stock following the positive late-stage trial results for its cancer vaccine, galinpepimut-S (GPS), for acute myeloid leukaemia.



















